HEB : Summary for Hemispherx BioPharma, Inc. - Yahoo Finance

U.S. Markets closed

Hemispherx Biopharma, Inc. (HEB)

NYSE MKT - NYSE MKT Real Time Price. Currency in USD
Add to watchlist
0.51-0.02 (-4.53%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.53
Bid0.00 x
Ask0.00 x
Day's Range0.50 - 0.52
52 Week Range0.39 - 2.64
Avg. Volume259,283
Market Cap13.22M
PE Ratio (TTM)-1.12
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017

    PHILADELPHIA, March 06, 2017-- Hemispherx Biopharma, Inc. announced today that it has met a major milestone, the commencement of sales of recently manufactured Ampligen in international programs. Hemispherx ...

  • Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks
    Insider Monkeylast month

    Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks

    By Khojinur Usmonov From low costs to expedited drug approval, President Trump recently met with big pharma CEOs about overhauling the entire system. Here’s what you need to know. A few weeks ago, President Donald Trump met with a series of biotech CEOs to discuss a historically major pain point for the industry: cutting the […]

  • American City Business Journals2 months ago

    $1M deal: Hemispherx plans to sell stock, warrants

    Hemispherx Biopharma Inc. entered into definitive agreements with several institutional investors under which the Philadelphia biotechnology company will receive gross proceeds of about $1 million through a sale of its common stock. Last week, Hemispherx announced that an order of newly manufactured Ampligen for sale using an Early Access Program to benefit patients suffering with chronic fatigue syndrome and pancreatic cancer in Europe had been shipped. In a letter to shareholders earlier this week, Hemispherx CEO Thomas K. Equels said the company expects to continue its discussions with the Food and Drug Administration to “identify a path forward” for Ampligen as a treatment for chronic fatigue syndrome.